Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited has reported promising preclinical data for avicursen (ATL1102), showing a 66% reduction in seizure frequency in a mouse model of autoimmune epilepsy. This positions avicursen as a potential new treatment option for a condition with limited current therapies, further validating its anti-inflammatory properties. The results also support the drug’s expansion into additional indications beyond Duchenne muscular dystrophy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
